This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
Researchers are testing an approved immunotherapy drug with a new drug that works on T cells to make it more effective for pancreatic cancer.
When treatment stopped working for Adam Deal, genetic testing of his tumor RNA found a mutation that made him eligible to try a new drug.
Researchers are testing an immunotherapy drug approved for other advanced cancers for effectiveness against pancreatic cancer.
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
A chemoradiation clinical trial tests standard chemotherapy plus an anti-malaria drug and compares two types of radiation treatments, to slow tumor growth.
A clinical trial uses a new immunotherapy drug in combination with standard chemotherapy drugs in metronomic therapy to treat metastatic pancreatic cancer.
Can vitamin D make it easier for chemotherapy drugs to reach the pancreatic cancer tumor? A clinical trial is testing this idea.
Rene Bernards and his team are targeting the signaling pathway of the KRAS mutation, which occurs in almost all pancreatic cancers.